Aussies suffering from Alzheimer’s disease may have avoided some sketchy science after drug development company Neuroscientific Biopharmaceuticals (ASX: NSB) had their application to commence Phase 1 trials in humans, rejected by the Human Research Ethics Committee (HREC). In order for any drug development company to commence trials in humans, they must secure HREC approvals which
Read More
The 60 million individuals around the world who suffer from glaucoma could one day have a cure for the debilitating eye disease from NeuroScientific Biopharmaceuticals (ASX: NSB), with the company buoyed by initial results from their preclinical trials. The drug development company’s lead product, EmtinB – a therapeutic peptide which has had positive results for
Read More